ClinicalTrials.gg
TerminatedNCT03166631Updated Nov 19, 2024Results posted

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

A Phase 1 interventional study of BI 891065 and BI 754091 in Neoplasms, Neoplasm Metastasis and Carcinoma, Non-Small-Cell Lung, sponsored by Boehringer Ingelheim. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Why this study was terminated
Not due to safety reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main objective of the dose-escalation parts of the trial is to determine the maximum tolerated dose (MTD), based on the frequency of patients experiencing dose-limiting toxicities (DLTs), and/or the recommended dose for further development of BI 891065 monotherapy as well as of BI 891065 in combination with BI 754091, and to evaluate its safety and tolerability by monitoring the occurrence and severity of adverse events (AEs).

Secondary objectives are the determination of the pharmacokinetic (PK) profile of BI 891065 monotherapy as well as of BI 891065 in combination with BI 754091, and the preliminary assessment of anti-tumour activity.

02

Conditions studied

  • Neoplasms
  • Neoplasm Metastasis
  • Carcinoma, Non-Small-Cell Lung
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 62 is close to the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written form (ICF) in accordance with International Conference of Harmonization-Good Clinical Practice (ICH-GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses
  • Patients ≥18 years-of-age at the time of signature of the ICF
  • Male or female patients. Women of (WOCBP) and men able to father a child must be ready and able to use highly effective methods of (that result in a low failure rate of less than 1% per year when used consistently and correctly)during trial participation and for at least 6 months after the last administration of trial medication. A list of contraception methods meeting these criteria is provided in the patient information.
  • (ECOG) score: 0 or 1
  • of at least 12 weeks after the start of the treatment according to the Investigator's judgement
  • For Parts A and B: Patients with a confirmed diagnosis of advanced, unresectable and/or solid tumours, who have failed standard treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to standard therapies. according to Version 1.1 must be present. Eligibility is limited to the following tumour subtypes in Part B: bladder, colon, breast, Non-small cell lung cancer (NSCLC), ovarian, pancreatic, renal, esophagogastric, sarcoma, prostate, and melanoma.
  • For Parts B and C: Patients must have measurable disease per RECIST v1.1, must have at least 1 tumour lesion amenable to , and must be willing to undergo a biopsy prior to first treatment and another biopsy while on therapy unless clinically .
  • For Part C: Patients with metastatic NSCLC who developed disease progression (per RECIST v1.1) after the first scan (where SD, Partial Response (PR), or Complete Response (CR) was demonstrated at the first scan), and require new anti-cancer therapy after treatment with an anti programmed cell death protein 1 ()/anti programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) (given either as single agent therapy or in combination with a platinum-based chemotherapy regimen).

Exclusion criteria

Exclusion criteria:

  • Major surgery (major according to the Investigator's and/or Medical Monitor's assessment) performed within 12 weeks prior to randomization or planned within 12 months after screening (e.g., hip replacement)
  • Presence of other active invasive cancers other than the one treated in this trial within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin, or in situ carcinoma of uterine cervix, or other local tumours considered cured by local treatment
  • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
  • Previous administration of BI 891065 or BI 754091
  • Currently enrolled in another device or drug trial, or less than 30 days since ending another investigational device or drug trial(s), or receiving other investigational treatments.
  • Patients who have been treated with any other anticancer drug within 4 weeks or within 5 half-life periods (whichever come earlier) prior to first administration of BI 891065. At least 7 days must have elapsed between the last dose of such agent and the first dose of study drug.
  • Persistent toxicity from previous treatments that has not resolved to ≤ Grade 1 (except for alopecia and Grade 2 neuropathy due to prior platinum-based therapy)
  • Active, known or suspected disease except vitiligo or resolved asthma/atopy
  • Interstitial lung disease
  • Any of the following cardiac criteria:

    • Mean resting interval (QTcF) >470 msec
    • Any abnormalities (as assessed by the investigator) in rhythm, conduction, or morphology of resting (ECGs), e.g., complete left bundle branch block, third degree heart block
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication with known or possible risk of QT interval prolongation
    • Patients with an (EF) \<55% or the lower limit of normal of the institutional standard will be excluded. Only in cases where the Investigator (or the treating physician or both) suspects cardiac disease with negative effect on the EF, will the EF be measured during screening using an appropriate method according to local standards to confirm eligibility (e.g., echocardiogram [ECHO], multi-gated acquisition scan [MUGA]). A historic measurement of EF no older than 6 months prior to first administration of study drug can be accepted provided that there is clinical evidence that the EF value has not worsened since this measurement in the opinion of the Investigator or of the treating physician or both.
  • Out of range laboratory values are defined as:

    • (ALT) and aspartate amino transferase (AST) >3 times the (ULN) if no demonstrable liver or >5 times ULN in the presence of liver metastases
    • Total >1.5 times ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin >3.0 times ULN or direct bilirubin >1.5 times ULN
  • (HIV) infection, acute or chronic viral hepatitis
  • Known to the trial drugs or their
  • Serious concomitant disease or medical condition affecting compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, such as cardiac, neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the Investigator and/or Medical Monitor would make the patient inappropriate for entry into the trial.
  • Chronic alcohol or drug abuse or any condition that, in the Investigator's and/or Medical Monitor's opinion, makes them an unreliable trial patient or unlikely to complete the trial
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial and for at least 6 months after the last administration of trial medication.
  • Men who plan to father a child while in the trial and for at least 6 months after the last administration of trial medication.
  • Known presence of symptomatic central nervous system (CNS) metastases, unless asymptomatic and off and/or anti-convulsant therapy for at least 2 weeks prior start of treatment. Patients with asymptomatic may be enrolled following a 2-week .
  • Patients receiving systemic treatment with any medication within 1 week prior treatment start (steroids of max. 10 mg prednisolone equivalent per day are allowed, topical and inhaled steroids are not considered as immunosuppressive).
  • For Parts A and B: Patients with known epidermal growth factor receptor (EGFR), known anaplastic lymphoma kinase (ALK), or known ROS Proto-Oncogene 1 (ROS1) genomic tumour aberrations, unless disease has progressed following available EGFR or ALK targeted therapy (including osimertinib for EGFR T790M-mutated NSCLC)
  • Out of range lab values as defined:

    • (ANC) \<1.5 x 109/L (\<1500/mm3)
    • (PLT) count \<100 x 109/L
  • \<90 g/L (\<9 g/dL)

    -- Creatinine >1.5 times ULN (patients may enter if creatinine is >1.5 x ULN and estimated (eGFR) >30 mL/min/1.73 m2) (Chronic Kidney Disease Epidemiology [CKD-EPI] Collaboration equation); confirmation of eGRF is only required when creatinine is >1.5 X ULN.

  • For Part C: Patients with EGFR, ALK, or (if known) ROS1 genomic tumor aberrations
  • For Part C: Patients with any therapy
  • For Part C: One or more lines of anti-cancer therapy between previous anti-PD-1/anti-PDL1 mAb therapy and study entry.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Part A: 5 mg BI 891065

    BI 891065 alone

    Drug: BI 891065

  • Experimental
    Part A: 15 mg BI 891065

    BI 891065 alone

    Drug: BI 891065

  • Experimental
    Part A: 25 mg BI 891065

    BI 891065 alone

    Drug: BI 891065

  • Experimental
    Part A: 50 mg BI 891065

    BI 891065 alone

    Drug: BI 891065

  • Experimental
    Part A: 100 mg BI 891065

    BI 891065 alone

    Drug: BI 891065

  • Experimental
    Part A: 200 mg BI 891065

    BI 891065 alone

    Drug: BI 891065

  • Experimental
    Part A: 400 mg BI 981065

    BI 891065 alone

    Drug: BI 891065

  • Experimental
    Part B: 50 mg BI 891065 QD + 240 mg BI 754091

    BI 891065 in combination with BI 754091

    Drug: BI 891065 · Drug: BI 754091

  • Experimental
    Part B: 200 mg BI 891065 QD + 240 mg BI 754091

    BI 891065 in combination with BI 754091

    Drug: BI 891065 · Drug: BI 754091

  • Experimental
    Part B: 400 mg BI 891065 QD + 240 mg BI 754091

    BI 891065 in combination with BI 754091

    Drug: BI 754091

  • Experimental
    Part B: 200 mg BI 981065 BID + 240 mg BI 754091

    BI 891065 in combination with BI 754091

    Drug: BI 891065 · Drug: BI 754091

Interventions

  • DrugBI 891065

    Part A, Part B

  • Part B

06

What researchers measure

Primary outcomes

  1. Part A - Maximum Tolerated Dose (MTD) of BI 891065

    Maximum tolerated dose (MTD) defined as the highest dose with less than 25% risk of the true Dose-limiting toxicity (DLT) rate being above 33% during the MTD evaluation period.

    Time frame: First treatment cycle (MTD evaluation period), up to 21 days.

  2. Part A - Number of Patients With Dose-limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) Evaluation Period

    DLT is defined as: Hematologic toxicities for patients with solid tumors: Any Grade 5 toxicity; Neutropenia ≥Grade 4 lasting for \>5 days; Febrile neutropenia of any duration; Neutropenia Grade 3 with documented infection; Grade thrombocytopenia 4, or Grade 3 with bleeding or require platelet transfusion; Grade 4 anemia unexplained by underlying disease. Non-hematological toxicities: AST or ALT \>3xULN and concurrent total bilirubin \>2xULN without initial findings of cholestasis; ≥Grade 4 AST or ALT; Any ≥Grade 3 non-hematologic toxicity with some exceptions listed in protocol; Any Grade 2 pneumonitis; Any Grade 2 related uveitis, eye pain, or blurred vision that does not respond to topical therapy and does not improve to Grade 1 severity within 2 weeks or requires systemic treatment; Any treatment-related ≥Grade 2 toxicity that persists and results in an inability to administer BI 754091 on Cycle 2 Day 1.

    Time frame: First treatment cycle (MTD evaluation period), up to 21 days.

  3. Part B: Maximum Tolerated Dose (MTD) of BI 891065 in Combination With Ezabenlimab

    Maximum tolerated dose (MTD) of BI 891065 in combination with ezabenlimab, defined as the highest dose with less than 25% risk of the true Dose-limiting toxicity (DLT) rate being above 33% during the MTD evaluation period.

    Time frame: First treatment cycle (MTD evaluation period), up to 21 days.

  4. Part B: Number of Patients With Dose-limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) Evaluation Period

    DLT is defined as: Hematologic toxicities for patients with solid tumors: Any Grade 5 toxicity; Neutropenia ≥Grade 4 lasting for \>5 days; Febrile neutropenia of any duration; Neutropenia Grade 3 with documented infection; Grade thrombocytopenia 4, or Grade 3 with bleeding or require platelet transfusion; Grade 4 anemia unexplained by underlying disease. Non-hematological toxicities: AST or ALT \>3xULN and concurrent total bilirubin \>2xULN without initial findings of cholestasis; ≥Grade 4 AST or ALT; Any ≥Grade 3 non-hematologic toxicity with some exceptions listed in protocol; Any Grade 2 pneumonitis; Any Grade 2 related uveitis, eye pain, or blurred vision that does not respond to topical therapy and does not improve to Grade 1 severity within 2 weeks or requires systemic treatment; Any treatment-related ≥Grade 2 toxicity that persists and results in an inability to administer BI 754091 on Cycle 2 Day 1.

    Time frame: First treatment cycle (MTD evaluation period), up to 21 days.

Secondary outcomes

  1. Part A: Number of Patients With Dose-limiting Toxicities (DLT) During the Entire On-treatment Period

    DLT is defined as: Hematologic toxicities for patients with solid tumors: Any Grade 5 toxicity; Neutropenia ≥Grade 4 lasting for \>5 days; Febrile neutropenia of any duration; Neutropenia Grade 3 with documented infection; Grade thrombocytopenia 4, or Grade 3 with bleeding or require platelet transfusion; Grade 4 anemia unexplained by underlying disease. Non-hematological toxicities: AST or ALT \>3xULN and concurrent total bilirubin \>2xULN without initial findings of cholestasis; ≥Grade 4 AST or ALT; Any ≥Grade 3 non-hematologic toxicity with some exceptions listed in protocol; Any Grade 2 pneumonitis; Any Grade 2 related uveitis, eye pain, or blurred vision that does not respond to topical therapy and does not improve to Grade 1 severity within 2 weeks or requires systemic treatment; Any treatment-related ≥Grade 2 toxicity that persists and results in an inability to administer BI 754091 on Cycle 2 Day 1.

    Time frame: From first drug administration until last drug administration plus residual effect period of 30 days, up to 282 days.

  2. Part A: Number of Patients With Objective Response (OR)

    OR based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, defined as the best overall response of complete response (CR) and partial response (PR), where the best overall response is the best time point response recorded from the first administration of study medication until the end of treatment Number of patients with objective response is reported.

    Time frame: Up to 252 days.

  3. Part A: Maximum Measured Plasma Concentration of BI 891065 at Steady State (Cmax,ss)

    Maximum measured plasma concentration at steady state (cmax,ss) during the first treatment cycle. Timeframe description: \*: Timepoint measured only for dose group 5 mg, 15 mg, 25 mg, and 50 mg. \*\*: Timepoint measured only for dose group 50 mg, 100 mg, 200 mg and 400 mg.

    Time frame: Just before drug intake and 0.5**, 1, 2, 3, 4*, 5, 6, 7, 8, 10**, 12*, 24, 36, 47.917, 167.917, 263.917, 335.917, 336.5**, 337, 338, 339, 340*, 341, 342, 343, 344, 346**, 348*, 359.917 hours after drug administration on day 1.

  4. Part A: Area Under the Concentration Time Curve of BI 891065 Over a Dosing Interval at Steady State (AUCtau,ss)

    Area under the concentration time curve of BI 891065 over a dosing interval at steady state (AUCtau,ss). Timeframe description: \*: Timepoint measured only for dose group 5 mg, 15 mg, 25 mg, and 50 mg. \*\*: Timepoint measured only for dose group 50 mg, 100 mg, 200 mg and 400 mg.

    Time frame: Just before drug intake and 0.5**, 1, 2, 3, 4*, 5, 6, 7, 8, 10**, 12*, 24, 36, 47.917, 167.917, 263.917, 335.917, 336.5**, 337, 338, 339, 340*, 341, 342, 343, 344, 346**, 348*, 359.917 hours after drug administration on day 1.

  5. Part A: Area Under the Concentration-time Curve of BI 891065 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of BI 891065 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) in the first treatment cycle. Timeframe description: \*: Timepoint measured only for dose group 5 mg, 15 mg, 25 mg, and 50 mg. \*\*: Timepoint measured only for dose group 50 mg, 100 mg, 200 mg and 400 mg.

    Time frame: Just before drug intake and 0.5**, 1, 2, 3, 4*, 5, 6, 7, 8, 10**, 12*, 24, 36, 47.917, 167.917, 263.917, 335.917, 336.5**, 337, 338, 339, 340*, 341, 342, 343, 344, 346**, 348*, 359.917 hours after drug administration on day 1.

  6. Part B: Number of Patients With Dose-limiting Toxicities (DLTs) Observed During the Entire Treatment Period

    DLT is defined as: Hematologic toxicities for patients with solid tumors: Any Grade 5 toxicity; Neutropenia ≥Grade 4 lasting for \>5 days; Febrile neutropenia of any duration; Neutropenia Grade 3 with documented infection; Grade thrombocytopenia 4, or Grade 3 with bleeding or require platelet transfusion; Grade 4 anemia unexplained by underlying disease. Non-hematological toxicities: AST or ALT \>3xULN and concurrent total bilirubin \>2xULN without initial findings of cholestasis; ≥Grade 4 AST or ALT; Any ≥Grade 3 non-hematologic toxicity with some exceptions listed in protocol; Any Grade 2 pneumonitis; Any Grade 2 related uveitis, eye pain, or blurred vision that does not respond to topical therapy and does not improve to Grade 1 severity within 2 weeks or requires systemic treatment; Any treatment-related ≥Grade 2 toxicity that persists and results in an inability to administer BI 754091 on Cycle 2 Day 1.

    Time frame: From first drug administration until last drug administration plus residual effect period of 30 days, up to 386 days.

  7. Part B: Number of Patients With Objective Response (OR)

    OR based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, defined as the best overall response of complete response (CR) and partial response (PR), where the best overall response is the best time point response recorded from the first administration of study medication until the end of treatment. Number of patients with objective response is reported.

    Time frame: Up to 356 days.

  8. Part B: Area Under the Concentration-time Curve of BI 891065 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of BI 891065 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) in the first treatment cycle.

    Time frame: At 1.417, 2, 2.5, 3.5, 4.5, 6.5, 7.5, 8.5, 9.5, 11.5, 25.417, 167.917, 263.917, 335.917, 336.5, 337, 338, 339, 341, 342, 343, 344, 346, 359.5, 360.5, 361, 362, 363, 365, 366, 367, 368, 370 and 383.917 hours after intake of BI 891065 at day 1, cycle 1.

  9. Part B: Area Under the Concentration Time Curve of BI 891065 Over a Dosing Interval at Steady State (AUCtau,ss)

    Area under the concentration time curve of BI 891065 over a dosing interval at steady state (AUCtau,ss) in the first treatment cycle.

    Time frame: At 1.417, 2, 2.5, 3.5, 4.5, 6.5, 7.5, 8.5, 9.5, 11.5, 25.417, 167.917, 263.917, 335.917, 336.5, 337, 338, 339, 341, 342, 343, 344, 346, 359.5, 360.5, 361, 362, 363, 365, 366, 367, 368, 370 and 383.917 hours after intake of BI 891065 at day 1, cycle 1.

  10. Part B: Maximum Measured Plasma Concentration of BI 891065 at Steady State (Cmax,ss)

    Maximum measured plasma concentration of BI 891065 at steady state (Cmax,ss) in the first treatment cycle.

    Time frame: At 1.417, 2, 2.5, 3.5, 4.5, 6.5, 7.5, 8.5, 9.5, 11.5, 25.417, 167.917, 263.917, 335.917, 336.5, 337, 338, 339, 341, 342, 343, 344, 346, 359.5, 360.5, 361, 362, 363, 365, 366, 367, 368, 370 and 383.917 hours after intake of BI 891065 at day 1, cycle 1.

  11. Part B: Maximum Measured Plasma Concentration (Cmax) of BI 754091 in the First Treatment Cycle

    Maximum measured plasma concentration (Cmax) of BI 754091 in the first treatment cycle. Results are reported for the overall group only since dose level of BI 754091 is fixed in this trial.

    Time frame: Predose and 1, 1.417, 2, 2.5, 3.5, 4.5, 6.5, 7.5, 8.5, 9.5, 11.5, 25.417, 167.917, 263.917, 335.917, 359.5, 383.917, 504, 998 and 999 hours after intake of BI 754091 at day 1, cycle 1.

  12. Part B: Area Under the Concentration-time Curve of BI 754091 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of BI 754091 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) in the first treatment cycle. Results are reported for the overall group only since dose level of BI 754091 is fixed in this trial.

    Time frame: Predose and 1, 1.417, 2, 2.5, 3.5, 4.5, 6.5, 7.5, 8.5, 9.5, 11.5, 25.417, 167.917, 263.917, 335.917, 359.5, 383.917, 504, 998 and 999 hours after intake of BI 754091 at day 1, cycle 1.

07

Results

Posted Nov 19, 2024

Participant flow

An open-label trial to investigate the maximum tolerated dose (MTD)/recommended dose for further development based on dose limiting toxicities (DLT), safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BI 891065 alone and in combination with BI 754091 in patients with advanced and/or metastatic malignancies.

Participant flow — Overall Study
MilestonePart A: 5 mg BI 891065Part A: 15 mg BI 891065Part A: 25 mg BI 891065Part A: 50 mg BI 891065Part A: 100 mg BI 891065Part A: 200 mg BI 891065Part A: 400 mg BI 891065Part B: 50 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 QD + 240 mg BI 754091Part B: 400 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 BID + 240 mg BI 754091
Started313433861489
Completed00000000000
Not completed313433861489
Withdrew: Progressive disease213422561157
Withdrew: Physician decision00000010101
Withdrew: Death00001010000
Withdrew: Adverse event10000110121
Withdrew: Withdrawal by subject00000000110

Outcome measures

PrimaryPart A - Maximum Tolerated Dose (MTD) of BI 891065

Maximum tolerated dose (MTD) defined as the highest dose with less than 25% risk of the true Dose-limiting toxicity (DLT) rate being above 33% during the MTD evaluation period.

Time frame:
First treatment cycle (MTD evaluation period), up to 21 days.
Reported as:
Number · Milligram
Part A - Maximum Tolerated Dose (MTD) of BI 891065
MilligramPart A: BI 891065
Part A - Maximum Tolerated Dose (MTD) of BI 891065NA
PrimaryPart A - Number of Patients With Dose-limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) Evaluation Period

DLT is defined as: Hematologic toxicities for patients with solid tumors: Any Grade 5 toxicity; Neutropenia ≥Grade 4 lasting for \>5 days; Febrile neutropenia of any duration; Neutropenia Grade 3 with documented infection; Grade thrombocytopenia 4, or Grade 3 with bleeding or require platelet transfusion; Grade 4 anemia unexplained by underlying disease. Non-hematological toxicities: AST or ALT \>3xULN and concurrent total bilirubin \>2xULN without initial findings of cholestasis; ≥Grade 4 AST or ALT; Any ≥Grade 3 non-hematologic toxicity with some exceptions listed in protocol; Any Grade 2 pneumonitis; Any Grade 2 related uveitis, eye pain, or blurred vision that does not respond to topical therapy and does not improve to Grade 1 severity within 2 weeks or requires systemic treatment; Any treatment-related ≥Grade 2 toxicity that persists and results in an inability to administer BI 754091 on Cycle 2 Day 1.

Time frame:
First treatment cycle (MTD evaluation period), up to 21 days.
Reported as:
Count of participants · Participants
Part A - Number of Patients With Dose-limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) Evaluation Period
ParticipantsPart A: 5 mg BI 891065Part A: 15 mg BI 891065Part A: 25 mg BI 891065Part A: 50 mg BI 891065Part A: 100 mg BI 891065Part A: 200 mg BI 891065Part A: 400 mg BI 891065
Part A - Number of Patients With Dose-limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) Evaluation Period0000000
SecondaryPart A: Number of Patients With Dose-limiting Toxicities (DLT) During the Entire On-treatment Period

DLT is defined as: Hematologic toxicities for patients with solid tumors: Any Grade 5 toxicity; Neutropenia ≥Grade 4 lasting for \>5 days; Febrile neutropenia of any duration; Neutropenia Grade 3 with documented infection; Grade thrombocytopenia 4, or Grade 3 with bleeding or require platelet transfusion; Grade 4 anemia unexplained by underlying disease. Non-hematological toxicities: AST or ALT \>3xULN and concurrent total bilirubin \>2xULN without initial findings of cholestasis; ≥Grade 4 AST or ALT; Any ≥Grade 3 non-hematologic toxicity with some exceptions listed in protocol; Any Grade 2 pneumonitis; Any Grade 2 related uveitis, eye pain, or blurred vision that does not respond to topical therapy and does not improve to Grade 1 severity within 2 weeks or requires systemic treatment; Any treatment-related ≥Grade 2 toxicity that persists and results in an inability to administer BI 754091 on Cycle 2 Day 1.

Time frame:
From first drug administration until last drug administration plus residual effect period of 30 days, up to 282 days.
Reported as:
Count of participants · Participants
Part A: Number of Patients With Dose-limiting Toxicities (DLT) During the Entire On-treatment Period
ParticipantsPart A: 5 mg BI 891065Part A: 15 mg BI 891065Part A: 25 mg BI 891065Part A: 50 mg BI 891065Part A: 100 mg BI 891065Part A: 200 mg BI 891065Part A: 400 mg BI 891065
Part A: Number of Patients With Dose-limiting Toxicities (DLT) During the Entire On-treatment Period0000000
SecondaryPart A: Number of Patients With Objective Response (OR)

OR based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, defined as the best overall response of complete response (CR) and partial response (PR), where the best overall response is the best time point response recorded from the first administration of study medication until the end of treatment Number of patients with objective response is reported.

Time frame:
Up to 252 days.
Reported as:
Count of participants · Participants
Part A: Number of Patients With Objective Response (OR)
ParticipantsPart A: 5 mg BI 891065Part A: 15 mg BI 891065Part A: 25 mg BI 891065Part A: 50 mg BI 891065Part A: 100 mg BI 891065Part A: 200 mg BI 891065Part A: 400 mg BI 891065
No3134338
Yes0000000
SecondaryPart A: Maximum Measured Plasma Concentration of BI 891065 at Steady State (Cmax,ss)

Maximum measured plasma concentration at steady state (cmax,ss) during the first treatment cycle. Timeframe description: \*: Timepoint measured only for dose group 5 mg, 15 mg, 25 mg, and 50 mg. \*\*: Timepoint measured only for dose group 50 mg, 100 mg, 200 mg and 400 mg.

Time frame:
Just before drug intake and 0.5**, 1, 2, 3, 4*, 5, 6, 7, 8, 10**, 12*, 24, 36, 47.917, 167.917, 263.917, 335.917, 336.5**, 337, 338, 339, 340*, 341, 342, 343, 344, 346**, 348*, 359.917 hours after drug administration on day 1.
Reported as:
Geometric mean · nanomol per Liter (nmol/L)
Part A: Maximum Measured Plasma Concentration of BI 891065 at Steady State (Cmax,ss)
nanomol per Liter (nmol/L)Part A: 5 mg BI 891065Part A: 15 mg BI 891065Part A: 25 mg BI 891065Part A: 50 mg BI 891065Part A: 100 mg BI 891065Part A: 200 mg BI 891065Part A: 400 mg BI 891065
Part A: Maximum Measured Plasma Concentration of BI 891065 at Steady State (Cmax,ss)86.3 ± 39.6163 ± NA948 ± 61.5708 ± 1231410 ± 56.03070 ± 88.32550 ± 68.5
SecondaryPart A: Area Under the Concentration Time Curve of BI 891065 Over a Dosing Interval at Steady State (AUCtau,ss)

Area under the concentration time curve of BI 891065 over a dosing interval at steady state (AUCtau,ss). Timeframe description: \*: Timepoint measured only for dose group 5 mg, 15 mg, 25 mg, and 50 mg. \*\*: Timepoint measured only for dose group 50 mg, 100 mg, 200 mg and 400 mg.

Time frame:
Just before drug intake and 0.5**, 1, 2, 3, 4*, 5, 6, 7, 8, 10**, 12*, 24, 36, 47.917, 167.917, 263.917, 335.917, 336.5**, 337, 338, 339, 340*, 341, 342, 343, 344, 346**, 348*, 359.917 hours after drug administration on day 1.
Reported as:
Geometric mean · Nanomol * hours per Liter
Part A: Area Under the Concentration Time Curve of BI 891065 Over a Dosing Interval at Steady State (AUCtau,ss)
Nanomol * hours per LiterPart A: 5 mg BI 891065Part A: 15 mg BI 891065Part A: 25 mg BI 891065Part A: 50 mg BI 891065Part A: 100 mg BI 891065Part A: 200 mg BI 891065Part A: 400 mg BI 891065
Part A: Area Under the Concentration Time Curve of BI 891065 Over a Dosing Interval at Steady State (AUCtau,ss)713 ± 33.82070 ± NA10600 ± 19010700 ± 91.518800 ± 72.251300 ± 87.548500 ± 57.5
SecondaryPart A: Area Under the Concentration-time Curve of BI 891065 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of BI 891065 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) in the first treatment cycle. Timeframe description: \*: Timepoint measured only for dose group 5 mg, 15 mg, 25 mg, and 50 mg. \*\*: Timepoint measured only for dose group 50 mg, 100 mg, 200 mg and 400 mg.

Time frame:
Just before drug intake and 0.5**, 1, 2, 3, 4*, 5, 6, 7, 8, 10**, 12*, 24, 36, 47.917, 167.917, 263.917, 335.917, 336.5**, 337, 338, 339, 340*, 341, 342, 343, 344, 346**, 348*, 359.917 hours after drug administration on day 1.
Reported as:
Geometric mean · Nanomol * hours per Liter
Part A: Area Under the Concentration-time Curve of BI 891065 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
Nanomol * hours per LiterPart A: 5 mg BI 891065Part A: 15 mg BI 891065Part A: 25 mg BI 891065Part A: 50 mg BI 891065Part A: 100 mg BI 891065Part A: 200 mg BI 891065Part A: 400 mg BI 891065
Part A: Area Under the Concentration-time Curve of BI 891065 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)281 ± 44.61930 ± NA5030 ± 1135820 ± 38.812900 ± 73.525200 ± 8.4935800 ± 51.0
PrimaryPart B: Maximum Tolerated Dose (MTD) of BI 891065 in Combination With Ezabenlimab

Maximum tolerated dose (MTD) of BI 891065 in combination with ezabenlimab, defined as the highest dose with less than 25% risk of the true Dose-limiting toxicity (DLT) rate being above 33% during the MTD evaluation period.

Time frame:
First treatment cycle (MTD evaluation period), up to 21 days.
Reported as:
Number · Milligram
Part B: Maximum Tolerated Dose (MTD) of BI 891065 in Combination With Ezabenlimab
MilligramPart B: BI 891065 + 240mg BI 754091
Part B: Maximum Tolerated Dose (MTD) of BI 891065 in Combination With EzabenlimabNA
PrimaryPart B: Number of Patients With Dose-limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) Evaluation Period

DLT is defined as: Hematologic toxicities for patients with solid tumors: Any Grade 5 toxicity; Neutropenia ≥Grade 4 lasting for \>5 days; Febrile neutropenia of any duration; Neutropenia Grade 3 with documented infection; Grade thrombocytopenia 4, or Grade 3 with bleeding or require platelet transfusion; Grade 4 anemia unexplained by underlying disease. Non-hematological toxicities: AST or ALT \>3xULN and concurrent total bilirubin \>2xULN without initial findings of cholestasis; ≥Grade 4 AST or ALT; Any ≥Grade 3 non-hematologic toxicity with some exceptions listed in protocol; Any Grade 2 pneumonitis; Any Grade 2 related uveitis, eye pain, or blurred vision that does not respond to topical therapy and does not improve to Grade 1 severity within 2 weeks or requires systemic treatment; Any treatment-related ≥Grade 2 toxicity that persists and results in an inability to administer BI 754091 on Cycle 2 Day 1.

Time frame:
First treatment cycle (MTD evaluation period), up to 21 days.
Reported as:
Number · Participants
Part B: Number of Patients With Dose-limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) Evaluation Period
ParticipantsPart B: 50 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 QD + 240 mg BI 754091Part B: 400 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 BID + 240 mg BI 754091
Part B: Number of Patients With Dose-limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) Evaluation Period0010
SecondaryPart B: Number of Patients With Dose-limiting Toxicities (DLTs) Observed During the Entire Treatment Period

DLT is defined as: Hematologic toxicities for patients with solid tumors: Any Grade 5 toxicity; Neutropenia ≥Grade 4 lasting for \>5 days; Febrile neutropenia of any duration; Neutropenia Grade 3 with documented infection; Grade thrombocytopenia 4, or Grade 3 with bleeding or require platelet transfusion; Grade 4 anemia unexplained by underlying disease. Non-hematological toxicities: AST or ALT \>3xULN and concurrent total bilirubin \>2xULN without initial findings of cholestasis; ≥Grade 4 AST or ALT; Any ≥Grade 3 non-hematologic toxicity with some exceptions listed in protocol; Any Grade 2 pneumonitis; Any Grade 2 related uveitis, eye pain, or blurred vision that does not respond to topical therapy and does not improve to Grade 1 severity within 2 weeks or requires systemic treatment; Any treatment-related ≥Grade 2 toxicity that persists and results in an inability to administer BI 754091 on Cycle 2 Day 1.

Time frame:
From first drug administration until last drug administration plus residual effect period of 30 days, up to 386 days.
Reported as:
Count of participants · Participants
Part B: Number of Patients With Dose-limiting Toxicities (DLTs) Observed During the Entire Treatment Period
ParticipantsPart B: 50 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 QD + 240 mg BI 754091Part B: 400 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 BID + 240 mg BI 754091
Part B: Number of Patients With Dose-limiting Toxicities (DLTs) Observed During the Entire Treatment Period0111
SecondaryPart B: Number of Patients With Objective Response (OR)

OR based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, defined as the best overall response of complete response (CR) and partial response (PR), where the best overall response is the best time point response recorded from the first administration of study medication until the end of treatment. Number of patients with objective response is reported.

Time frame:
Up to 356 days.
Reported as:
Count of participants · Participants
Part B: Number of Patients With Objective Response (OR)
ParticipantsPart B: 50 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 QD + 240 mg BI 754091Part B: 400 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 BID + 240 mg BI 754091
No61489
Yes0000
SecondaryPart B: Area Under the Concentration-time Curve of BI 891065 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of BI 891065 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) in the first treatment cycle.

Time frame:
At 1.417, 2, 2.5, 3.5, 4.5, 6.5, 7.5, 8.5, 9.5, 11.5, 25.417, 167.917, 263.917, 335.917, 336.5, 337, 338, 339, 341, 342, 343, 344, 346, 359.5, 360.5, 361, 362, 363, 365, 366, 367, 368, 370 and 383.917 hours after intake of BI 891065 at day 1, cycle 1.
Reported as:
Geometric mean · Hours*nanomol / Liter
Part B: Area Under the Concentration-time Curve of BI 891065 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
Hours*nanomol / LiterPart B: 50 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 QD + 240 mg BI 754091Part B: 400 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 BID + 240 mg BI 754091
Part B: Area Under the Concentration-time Curve of BI 891065 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)3450 ± 44.417200 ± 82.931400 ± 56.520300 ± 71.6
SecondaryPart B: Area Under the Concentration Time Curve of BI 891065 Over a Dosing Interval at Steady State (AUCtau,ss)

Area under the concentration time curve of BI 891065 over a dosing interval at steady state (AUCtau,ss) in the first treatment cycle.

Time frame:
At 1.417, 2, 2.5, 3.5, 4.5, 6.5, 7.5, 8.5, 9.5, 11.5, 25.417, 167.917, 263.917, 335.917, 336.5, 337, 338, 339, 341, 342, 343, 344, 346, 359.5, 360.5, 361, 362, 363, 365, 366, 367, 368, 370 and 383.917 hours after intake of BI 891065 at day 1, cycle 1.
Reported as:
Geometric mean · Hours*nanomol/Liter
Part B: Area Under the Concentration Time Curve of BI 891065 Over a Dosing Interval at Steady State (AUCtau,ss)
Hours*nanomol/LiterPart B: 50 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 QD + 240 mg BI 754091Part B: 400 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 BID + 240 mg BI 754091
Part B: Area Under the Concentration Time Curve of BI 891065 Over a Dosing Interval at Steady State (AUCtau,ss)7260 ± 91.050600 ± 78.044000 ± 49.134400 ± 88.0
SecondaryPart B: Maximum Measured Plasma Concentration of BI 891065 at Steady State (Cmax,ss)

Maximum measured plasma concentration of BI 891065 at steady state (Cmax,ss) in the first treatment cycle.

Time frame:
At 1.417, 2, 2.5, 3.5, 4.5, 6.5, 7.5, 8.5, 9.5, 11.5, 25.417, 167.917, 263.917, 335.917, 336.5, 337, 338, 339, 341, 342, 343, 344, 346, 359.5, 360.5, 361, 362, 363, 365, 366, 367, 368, 370 and 383.917 hours after intake of BI 891065 at day 1, cycle 1.
Reported as:
Geometric least squares mean · Nanomol/Liter
Part B: Maximum Measured Plasma Concentration of BI 891065 at Steady State (Cmax,ss)
Nanomol/LiterPart B: 50 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 QD + 240 mg BI 754091Part B: 400 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 BID + 240 mg BI 754091
Part B: Maximum Measured Plasma Concentration of BI 891065 at Steady State (Cmax,ss)623 ± 77.03010 ± 67.83220 ± 33.43460 ± 79.5
SecondaryPart B: Maximum Measured Plasma Concentration (Cmax) of BI 754091 in the First Treatment Cycle

Maximum measured plasma concentration (Cmax) of BI 754091 in the first treatment cycle. Results are reported for the overall group only since dose level of BI 754091 is fixed in this trial.

Time frame:
Predose and 1, 1.417, 2, 2.5, 3.5, 4.5, 6.5, 7.5, 8.5, 9.5, 11.5, 25.417, 167.917, 263.917, 335.917, 359.5, 383.917, 504, 998 and 999 hours after intake of BI 754091 at day 1, cycle 1.
Reported as:
Geometric least squares mean · Microgram/milliliter
Part B: Maximum Measured Plasma Concentration (Cmax) of BI 754091 in the First Treatment Cycle
Microgram/milliliterPart B: 891065 + 240 mg BI 754091 - Overall
Part B: Maximum Measured Plasma Concentration (Cmax) of BI 754091 in the First Treatment Cycle79.7 ± 22.2
SecondaryPart B: Area Under the Concentration-time Curve of BI 754091 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of BI 754091 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) in the first treatment cycle. Results are reported for the overall group only since dose level of BI 754091 is fixed in this trial.

Time frame:
Predose and 1, 1.417, 2, 2.5, 3.5, 4.5, 6.5, 7.5, 8.5, 9.5, 11.5, 25.417, 167.917, 263.917, 335.917, 359.5, 383.917, 504, 998 and 999 hours after intake of BI 754091 at day 1, cycle 1.
Reported as:
Geometric least squares mean · Hours*micorgram/milliliter
Part B: Area Under the Concentration-time Curve of BI 754091 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
Hours*micorgram/milliliterPart B: 891065 + 240 mg BI 754091 - Overall
Part B: Area Under the Concentration-time Curve of BI 754091 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)13100 ± 48.7

Adverse events

Collected over Part A: From first drug administration until last drug administration plus 30 days residual effect period (REP), up to 282 days. Part B: From first drug administration until last drug administration plus 30 days residual effect period (REP), up to 386. Number of deaths differ compared to number in participant flow, due to different timeframe.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: 5 mg BI 8910651/3 (33.3%)1/3 (33.3%)3/3 (100%)
Part A: 15 mg BI 8910651/1 (100%)0/1 (0%)1/1 (100%)
Part A: BI 891065 25 mg2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Part A: BI 891065 50 mg3/4 (75%)1/4 (25%)4/4 (100%)
Part A: 100 mg BI 8910652/3 (66.7%)2/3 (66.7%)3/3 (100%)
Part A: 200 mg BI 8910651/3 (33.3%)1/3 (33.3%)2/3 (66.7%)
Part A: 400 mg BI 8910652/8 (25%)2/8 (25%)8/8 (100%)
Part B: 50 mg BI 891065 QD + 240 mg BI 7540912/6 (33.3%)0/6 (0%)6/6 (100%)
Part B: 200 mg BI 891065 QD + 240 mg BI 7540912/14 (14.3%)3/14 (21.4%)13/14 (92.9%)
Part B: 400 mg BI 891065 QD + 240 mg BI 7540910/8 (0%)3/8 (37.5%)8/8 (100%)
Part B: 200 mg BI 891065 BID + 240 mg BI 7540913/9 (33.3%)2/9 (22.2%)9/9 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPart A: 5 mg BI 891065Part A: 15 mg BI 891065Part A: BI 891065 25 mgPart A: BI 891065 50 mgPart A: 100 mg BI 891065Part A: 200 mg BI 891065Part A: 400 mg BI 891065Part B: 50 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 QD + 240 mg BI 754091Part B: 400 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 BID + 240 mg BI 754091
Septic shockInfections and infestations0/30/10/30/40/31/30/80/60/140/80/9
DeliriumPsychiatric disorders0/30/10/30/41/30/30/80/60/140/80/9
Acute kidney injuryRenal and urinary disorders0/30/10/30/41/30/30/80/60/141/81/9
Renal failureRenal and urinary disorders1/30/10/30/40/30/30/80/60/140/80/9
HypoxiaRespiratory, thoracic and mediastinal disorders0/30/11/31/40/30/30/80/61/140/80/9
Respiratory arrestRespiratory, thoracic and mediastinal disorders0/30/10/30/41/30/30/80/60/140/80/9
Confusional statePsychiatric disorders0/30/10/31/40/30/30/80/60/140/80/9
Laryngeal haemorrhageRespiratory, thoracic and mediastinal disorders0/30/10/31/40/30/30/80/60/140/80/9
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/30/10/31/40/30/30/80/60/140/80/9
Angina pectorisCardiac disorders0/30/10/30/40/30/30/80/60/141/80/9
Most frequent other events
Showing 10 of 140
Most frequent other events
EventPart A: 5 mg BI 891065Part A: 15 mg BI 891065Part A: BI 891065 25 mgPart A: BI 891065 50 mgPart A: 100 mg BI 891065Part A: 200 mg BI 891065Part A: 400 mg BI 891065Part B: 50 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 QD + 240 mg BI 754091Part B: 400 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 BID + 240 mg BI 754091
DiarrhoeaGastrointestinal disorders1/31/11/31/40/30/32/82/64/142/82/9
FatigueGeneral disorders3/30/10/32/40/31/33/81/65/147/87/9
CoughRespiratory, thoracic and mediastinal disorders0/31/10/32/41/31/31/80/61/140/80/9
NauseaGastrointestinal disorders0/30/10/32/40/30/35/83/63/147/83/9
Urinary tract infectionInfections and infestations0/30/10/30/40/30/31/84/61/142/80/9
VomitingGastrointestinal disorders1/30/10/30/41/30/31/81/62/145/83/9
PyrexiaGeneral disorders0/30/10/31/40/31/30/80/61/143/85/9
Blood bilirubin increasedInvestigations0/30/10/30/40/30/34/80/67/143/85/9
FallInjury, poisoning and procedural complications0/30/10/32/40/30/30/81/60/141/81/9
Decreased appetiteMetabolism and nutrition disorders0/30/10/31/40/30/31/83/62/142/83/9

Baseline characteristics

Treated Set (TS) (Part A): The TS (Part A) included all patients who received at least one dose of BI 891065. Treated Set (TS) (Part B): The TS (Part B) included all patients who received at least one dose of BI 891065 or BI 754091.

Age, Continuous
Age, Continuous(Years)Part A: 5 mg BI 891065Part A: 15 mg BI 891065Part A: 25 mg BI 891065Part A: 50 mg BI 891065Part A: 100 mg BI 891065Part A: 200 mg BI 891065Part A: 400 mg BI 891065Part B: 50 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 QD + 240 mg BI 754091Part B: 400 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 BID + 240 mg BI 754091Total
Mean76.0 ± 2.658.0 ± NA65.7 ± 5.570.8 ± 9.563.0 ± 5.356.7 ± 15.466.5 ± 9.973.3 ± 6.760.4 ± 10.265.5 ± 10.358.7 ± 6.264.42 ± 9.94
Sex: Female, Male
Sex: Female, Male(Participants)Part A: 5 mg BI 891065Part A: 15 mg BI 891065Part A: 25 mg BI 891065Part A: 50 mg BI 891065Part A: 100 mg BI 891065Part A: 200 mg BI 891065Part A: 400 mg BI 891065Part B: 50 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 QD + 240 mg BI 754091Part B: 400 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 BID + 240 mg BI 754091Total
Female2032315494437
Male1102023254525
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: 5 mg BI 891065Part A: 15 mg BI 891065Part A: 25 mg BI 891065Part A: 50 mg BI 891065Part A: 100 mg BI 891065Part A: 200 mg BI 891065Part A: 400 mg BI 891065Part B: 50 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 QD + 240 mg BI 754091Part B: 400 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 BID + 240 mg BI 754091Total
Hispanic or Latino000000002002
Not Hispanic or Latino31243385128958
Unknown or Not Reported001000010002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: 5 mg BI 891065Part A: 15 mg BI 891065Part A: 25 mg BI 891065Part A: 50 mg BI 891065Part A: 100 mg BI 891065Part A: 200 mg BI 891065Part A: 400 mg BI 891065Part B: 50 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 QD + 240 mg BI 754091Part B: 400 mg BI 891065 QD + 240 mg BI 754091Part B: 200 mg BI 891065 BID + 240 mg BI 754091Total
American Indian or Alaska Native000000000000
Asian000000000000
Native Hawaiian or Other Pacific Islander000000000000
Black or African American001200000003
White31223386138958
More than one race000000000000
Unknown or Not Reported000000001001
08

Study locations

3 sites
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Froedtert and The Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Sep 2020, 36 months.

Results were first posted in Nov 2024, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2017
First posted
May 25, 2017
StartActual
Sep 8, 2017
Primary completionActual
Sep 15, 2020
CompletionActual
Oct 28, 2020
Results first posted
Nov 19, 2024
Last update
Nov 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03166631
Responsible party
Sponsor
First posted
May 25, 2017
Start date
Sep 8, 2017
Primary completion
Sep 15, 2020
Completion
Oct 28, 2020
Results posted
Nov 19, 2024
Last update
Nov 19, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ezabenlimab

Start the discussion